Beta blocker and angiotensin-converting enzyme inhibitor therapy is associated with decreased Th1/Th2 cytokine ratios and inflammatory cytokine production in patients with chronic heart failure

NeuroImmunoModulation

Volumn 11, Issue 3, 2004, Pages 173-180

  Gage, Julia R ^a   Fonarow, Gregg ^a   Hamilton, Michele ^a   Widawski, Mel ^b   Martínez Maza, Otoniel ^a   Vredevoe, Donna L ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Blocker; Angiotensin converting enzyme inhibitor; Cytokines; Heart failure; Interleukin 6; Th1; Th2

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CD28 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 6; NORADRENALIN; TUMOR NECROSIS FACTOR ALPHA;

ADRENERGIC SYSTEM; ADULT; AGED; ARTICLE; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HEART FAILURE; HUMAN; IMMUNE FUNCTION TEST; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; RUGBY; SUPERNATANT; TH1 CELL; TH2 CELL;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIGENS, CD3; CD4-POSITIVE T-LYMPHOCYTES; CHRONIC DISEASE; CYTOKINES; DOWN-REGULATION; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; INFLAMMATION; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-6; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; NOREPINEPHRINE; TH1 CELLS; TH2 CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 1842611509     PISSN: 10217401     EISSN: None     Source Type: Journal    
DOI: 10.1159/000076766     Document Type: Article

References (46)

1. Esler M, Kaye D, Lambert G, Esler D, Jennings G: Adrenergic nervous system in heart failure. Am J Cardiol 1997;80:7L-14L.
2. Terpening CM: Mediators of chronic heart failure: How drugs work. Ann Pharmacother 2001;35:1066-1074.
3. Bristow MR, Minobe WA, Raynolds MV, Port JD, Rasmussen R, Ray PE, Feldman AM: Reduced beta 1 receptor messenger RNA abundance in the failing human heart. J Clin Invest 1993;92:2737-2745.
4. McDevitt DG: Pharmacological characteristics of beta blockers and their role in clinical practice. J Cardiovasc Pharmacol 1986;8(suppl 6):S5-S11.
5. Bonet S, Agusti A, Arnau JM, Vidal X, Diogene E, Galve E, Laporte JR: Beta-adrenergic blocking agents in heart failure: Benefits of vasodilating and non-vasodilating agents according to patients' characteristics: A metaanalysis of clinical trials. Arch Intern Med 2000;160:621-627.
6. Erdmann E, Lechat P, Verkenne P, Wiemann H: Results from post-hoc analyses of the CIBIS II trial: Effect of bisoprolol in high-risk patient groups with chronic heart failure. Eur J Heart Fail 2001;3:469-479.
7. Levi R, Silver RB, Mackins CJ, Seyedi N, Koyama M: Activation of a renin-angiotensin system in ischemic cardiac sympathetic nerve endings and its association with norepinephrine release. Int Immunopharmacol 2002;2:1965-1973.
8. Dendorfer A, Thornagel A, Raasch W, Grisk O, Tempel K, Dominiak P: Angiotensin II induces catecholamine release by direct ganglionic excitation. Hypertension 2002;40:348-354.
9. Ruiz-Ortega M, Ruperez M, Lorenzo O, Esteban V, Blanco J, Mezzano S, Egido J: Angiotensin II regulates the synthesis of proinflammatory cytokines and chemokines in the kidney. Kidney Int Suppl 2002;82:12-22.
10. iα. J Pharmacol Exp Ther 2003;304:370-379.
11. Garg R, Yusuf S: Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995;273:1450-1456.
12. Flather MD, Yusuf S, Kober L, Pfeffer M, Hall A, Murray G, Torp-Pedersen C, Ball S, Pogue J, Moye L, Braunwald E: Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: A systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000;355:1575-1581.
13. Khan MM, Sansoni P, Silverman ED, Engleman EG, Melmon KL: Beta-adrenergic receptors on human suppressor, helper, and cytolytic lymphocytes. Biochem Pharmacol 1986;35:1137-1142.
14. Benschop RJ, Nieuwenhuis EE, Tromp EA, Godaert GL, Ballieux RE, van Doornen LJ: Effects of beta-adrenergic blockade on immunologic and cardiovascular changes induced by mental stress. Circulation 1994;89:762-769.
15. Kohm AP, Sanders VM: Norepinephrine and β2-adrenergic receptor stimulation regulate CD4+ T and B lymphocyte function in vitro and in vivo. Pharmacol Rev 2001;53:487-525.
16. Vredevoe DL, Moser DK, Gan X-H, Bonavida B: Natural killer cell anergy to cytokine stimulants in a subgroup of patients with heart failure: Relationship to norepinephrine. Neuroimmunomodulation 1995;2:16-24.
17. 1b phase of the cell cycle is required for completion of human immunodeficiency virus type 1 reverse transcription in T cells. J Virol 1998;72:3161-3168.
18. Fisher RA, Yates F: Statistical Tables for Biological, Agricultural and Medical Research, ed 6. Edinburgh, Oliver & Boyd, 1963.
19. Breen EC, van der Meijden M, Cumberland W, Kishimoto T, Detels R, Martínez-Maza O: The development of AIDS-associated Burkitt's/small noncleaved cell lymphoma is preceded by elevated serum levels of interleukin 6. Clin Immunol 1999;92:293-299.
20. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T: Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819-823.
21. Yoshikawa T, Handa S, Anzai T, Nishimura H, Baba A, Akaishi M, Mitamura H, Ogawa S: Early reduction of neurohumoral factors plays a key role in mediating the efficacy of beta-blocker therapy for congestive heart failure. Am Heart J 1996;131:329-336.
22. Aronson D, Burger AJ: Effect of beta-blockade on autonomic modulation of heart rate and neurohormonal profile in decompensated heart failure. Ann Noninvasive Electrocardiol 2001;6:98-106.
23. Bristow MR: β-Adrenergic receptor blockade in chronic heart failure. Circulation 2000;101:558-569.
24. Azevedo ER, Kubo T, Mak S, Al-Hesayen A, Schofield A, Allan R, Kelly S, Newton GE, Floras JS, Parker JD: Nonselective versus selective beta-adrenergic receptor blockade in congestive heart failure: Differential effects on sympathetic activity. Circulation 2001;104:2194-2199.
25. Woodley SL, Gilbert EM, Anderson JL, O'Connell JB, Deitchman D, Yanowitz FG, Mealey PC, Volkman K, Renlund DG, Menlove R: Beta-blockade with bucindolol in heart failure caused by ischemic versus idiopathic dilated cardiomyopathy. Circulation 1991;84:2426-2441.
26. Hara Y, Hamada M, Shigematsu Y, Murakami B, Hiwada K: Beneficial effect of beta-adrenergic blockade on left ventricular function in haemodialysis patients. Clin Sci (Lond) 2001;101:219-225.
27. Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, Deedwania PC, Ney DE, Snavely DB, Chang PI, on behalf of ELITE Study Investigators: Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349:747-752.
28. Baruch L, Anand I, Cohen IS, Ziesche S, Judd D, Cohn JN: Augmented short-and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group. Circulation 1999;99:2658-2664.
29. Fahy G, Deb B, Robinson K, Graham I: The effects of lisinopril on serum catecholamine concentrations both at rest and on exercise in patients with congestive cardiac failure. A double blind, placebo controlled, parallel group study. Ir Med J 1993;86:134-135.
30. Sheth T, Parker T, Block A, Hall C, Adam A, Pfeffer MA, Stewart DJ, Qian C, Rouleau JL; IMPRESS Investigators: Comparison of the effects of omapatrilat and lisinopril on circulating neurohormones and cytokines in patients with chronic heart failure. Am J Cardiol 2002;90:496-500.
31. Sanders VM, Baker RA, Ramer-Quinn DS, Kasprowicz DJ, Fuchs BA, Street NE: Differential expression of the beta-2-adrenergic receptor by Th1 and Th2 clones: Implications for cytokine production and B cell help. J Immunol 1997;158:4200-4210.
32. Maisel AS, Knowlton KU, Fowler P, Reardon A, Ziegler MG, Motulsky HJ, Insel PA, Michel MC: Adrenergic control of circulating lymphocyte subpopulations. Effects of congestive heart failure, dynamic exercise, and terbutaline treatment. J Clin Invest 1990;85:462-467.
33. Benschop RJ, Rodriguez-Feuerhahn M, Schedlowski M: Catecholamine-induced leukocytosis: Early observations, current research, and future directions. Brain Behav Immun 1996;10:77-91.
34. Elenkov IJ, Chrousos GP: Stress, cytokine patterns and susceptibility to disease. Baillières Best Pract Res Clin Endocrinol Metab 1999;13:583-595.
35. Swanson MA, Lee WT, Sanders VM: IFN-gamma production by Th1 cells generated from naïve CD4(+) T cells exposed to norepinephrine. J Immunol 2001;166:232-240.
36. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL: Cytokines and cytokine receptors in advanced heart failure. An analysis of the cytokine database from the vesnarinone trial (VEST). Circulation 2001;103:2055-2059.
37. Torre-Amione G, Kapadia S, Benedict CR, Oral H, Young JB, Mann DL: Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the studies of left ventricular dysfunction (SOLVD). J Am Coll Cardiol 1996;27:1201-1206.
38. Rauchhaus M, Doehner W, Francis DP, Davos C, Kemp M, Liebenthal C, Niebauer J, Hooper J, Volk HD, Coats AJ, Anker SD: Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation 2000;102:3060-3067.
39. Tsutamoto T, Hisanaga T, Wada A, Maeda K, Ohnishi M, Fukai D, Mabuchi N, Sawaki M, Kinoshita M: Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure. J Am Coll Cardiol 1998;31:391-398.
40. Black PH: Stress and the inflammatory response: A review of neurogenic inflammation. Brain Behav Immun 2002;16:622-653.
41. Mabuchi N, Tsutamoto T, Kinoshita M: Therapeutic use of dopamine and beta-blockers modulates plasma interleukin-6 levels in patients with congestive heart failure. J Cardiovasc Pharmacol 2000;36(suppl 2):S87-91.
42. Matsumura T, Tsushima K, Ohtaki E, Misu K, Tohbaru T, Asano R, Nagayama M, Kitahara K, Umemura J, Sumiyoshi T, Hosoda S: Effects of carvedilol on plasma levels of interleukin-6 and tumor necrosis factor-alpha in nine patients with dilated cardiomyopathy. J Cardiol 2002;39:253-257.
43. Gullestad L, Aukrust P, Ueland T, Espevik T, Yee G, Vagelos R, Frøland SS, Fowler M: Effect of high- versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. J Am Coll Cardiol 1999;34:2061-2067.
44. Murray DR, Prabhu SD, Chandrasekar B: Chronic beta-adrenergic stimulation induces myocardial proinflammatory cytokine expression. Circulation 2000;101:2338.
45. Elenkov IJ, Hasko G, Kovacs KJ, Vizi ES: Modulation of lipopolysaccharide-induced tumor necrosis factor alpha production by selective alpha- and beta-adrenergic drugs in mice. J Neuroimmunol 1995;61:123-131.
46. Ohtsuka T, Hamada M, Saeki H, Ogimoto A, Hiasa G, Hara Y, Shigematsu Y, Hiwada K: Comparison of effects of carvedilol versus metoprolol on cytokine levels in patients with idiopathic dilated cardiomyopathy. Am J Cardiol 2002;89:996-999.